Related Experiment Video

Updated: Aug 6, 2026

Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo
07:46

Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo

Published on: October 11, 2022

Claudins: emerging targets for cancer therapy

Scott L Kominsky1

  • 1Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, 720 Rutland Ave, Baltimore, MD 21205, USA. kominsc@jhmi.edu

Expert Reviews in Molecular Medicine
|August 5, 2006
PubMed

Insights

Claudins (CLDNs) are proteins crucial for cell junctions. Overexpressed in cancers, CLDNs show promise as therapeutic targets for cancer treatment, with preclinical studies demonstrating successful targeting strategies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Claudins (CLDNs) are transmembrane proteins essential for epithelial and endothelial tight junctions.
  • Beyond structural roles, CLDNs may influence cytoskeleton maintenance and cell signaling pathways.
  • Aberrant expression of specific CLDNs is increasingly observed in diverse cancer types.

Purpose of the Study:

  • To review the role of Claudins (CLDNs) in cancer.
  • To explore the potential of CLDNs as therapeutic targets in oncology.
  • To summarize current preclinical strategies for targeting CLDN-expressing tumors.

Main Methods:

  • Literature review of studies on Claudin (CLDN) expression in cancer.
  • Analysis of preclinical data on CLDN-targeted cancer therapies.
  • Evaluation of potential therapeutic approaches including antibody and enterotoxin treatments.

Main Results:

  • Claudins (CLDNs) are differentially expressed in tumor versus normal cells, with some members overexpressed in various cancers.
  • Preclinical models demonstrate successful targeting of CLDN-overexpressing tumor cells.
  • Therapeutic strategies include anti-CLDN antibodies and Clostridium perfringens enterotoxin.

Conclusions:

  • Claudins (CLDNs) represent promising targets for novel cancer therapies due to their differential expression and membrane localization.
  • CLDN-targeted therapeutics, including antibodies and enterotoxins, show potential in preclinical settings.
  • Further investigation into potential systemic toxicity is warranted, but CLDN-targeted approaches offer hope for cancer treatment.

More Related Videos

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro13:20

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro

Published on: July 17, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tight Junctions01:29

Tight Junctions

Tight junctions are molecular seals between cells that prevent the leaking of fluids, ions, and other small solutes across cavities and compartments in multicellular organisms. They are mainly composed of claudin and occludin transmembrane proteins, and other proteins such as tricellulin and JAM (junctional adhesion molecule). All these proteins are 4-pass transmembrane proteins, except JAM, which is a single-pass transmembrane protein belonging to the immunoglobulin superfamily. The...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...